Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion‐positive non–small cell lung cancer

The authors' previous study demonstrated that the B‐cell chronic lymphocytic leukemia/lymphoma (Bcl‐2)‐like 11 (BCL2L11) (Bim) deletion polymorphism was associated with poor clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with non–small cell lung cancer (NSCLC) with EGFR mutations. The objective of the current study was to investigate the impact of the Bim deletion polymorphism among patients with anaplastic lymphoma kinase (ALK)‐positive or ROS proto‐oncogene 1, receptor tyrosine kinase (ROS1)‐positive NSCLC who were treated with crizotinib.

[1]  X. Roca,et al.  Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer , 2016, Clinical Cancer Research.

[2]  T. Clackson,et al.  Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[3]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.

[4]  Xiaozhen Liu,et al.  Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement , 2016, Oncotarget.

[5]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[6]  Huanyu Chen,et al.  FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib , 2016, Clinical Cancer Research.

[7]  S. Asthana,et al.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer , 2015, Nature Medicine.

[8]  J. Ahn,et al.  The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Jingyun Shi,et al.  High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  B. Besse,et al.  Therapeutic management of ALK+ nonsmall cell lung cancer patients , 2015, European Respiratory Journal.

[11]  Sean Khozin,et al.  FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[12]  K. Matsuo,et al.  Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[14]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[15]  Jih-Hsiang Lee,et al.  Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  S. Ramalingam,et al.  ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options , 2014, Cancer.

[17]  F. Hirsch,et al.  The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer , 2014, Cancer.

[18]  William Pao,et al.  Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer , 2014, Nature Medicine.

[19]  A. Iyoda,et al.  Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  F. Hirsch,et al.  Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  H. Min,et al.  Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  C. Zhou,et al.  ROS1 fusions in Chinese patients with non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[24]  Y. Hasegawa,et al.  EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. , 2013, Cancer research.

[25]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Iafrate,et al.  Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. , 2012, The oncologist.

[27]  S. Ren,et al.  Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma , 2012, Cell Biochemistry and Biophysics.

[28]  S. Ren,et al.  Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma , 2012, Cancer.

[29]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[30]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[31]  P. Jänne,et al.  Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells , 2012, British Journal of Cancer.

[32]  W. Franklin,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[33]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[34]  Wei Zheng,et al.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.

[35]  S. Digumarthy,et al.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. , 2011, Cancer discovery.

[36]  P. Jänne,et al.  Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer , 2011, Clinical Cancer Research.

[37]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[38]  Y. Yatabe,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[39]  P. Jänne,et al.  The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.

[40]  Ceri M. Wiggins,et al.  Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics , 2009, The FEBS journal.

[41]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Tenen,et al.  BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations , 2007, PLoS medicine.

[43]  W. Pao,et al.  Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas , 2007, PLoS medicine.

[44]  A. Strasser,et al.  Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics , 2007, PLoS medicine.

[45]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[46]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[47]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.